Yoseph Shaaltiel Insider Trading $PLX Protalix BioTherapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Yoseph Shaaltiel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Yoseph Shaaltiel. Yoseph Shaaltiel is Executive VP, R&D in Protalix BioTherapeutics, Inc. ($PLX).
Yoseph Shaaltiel in Protalix BioTherapeutics, Inc.
Trading Symbol: PLXIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Yoseph Shaaltiel: Executive VP, R&D
Holdings: 883,754 shares
Current Value: $698,166
Latest Transaction: Mar 25 2010
$PLX Market Capitalization: $78.10M
$PLX Previous Close: $0.79
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Yoseph Shaaltiel in Protalix BioTherapeutics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.00 | 50,000 | 350,000 | 883,754 | 933.8 K to 883.8 K (-5.35 %) |
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.08 | 202,700 | 1,435,116 | 933,754 | 1.1 M to 933.8 K (-17.84 %) |
Mar 25 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 7.02 | 127,300 | 893,646 | 1,136,454 | 1.3 M to 1.1 M (-10.07 %) |
Feb 26 2010 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Option Exercise | A | 6.90 | 145,000 | 1,000,500 | 145,000 | |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.43 | 43,120 | 406,622 | 1,263,754 | 1.3 M to 1.3 M (-3.30 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.39 | 25,680 | 241,135 | 1,306,874 | 1.3 M to 1.3 M (-1.93 %) |
Oct 19 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 9.39 | 31,200 | 292,968 | 1,332,554 | 1.4 M to 1.3 M (-2.29 %) |
Jul 08 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 4.95 | 20,000 | 99,000 | 1,363,754 | 1.4 M to 1.4 M (-1.45 %) |
Jul 08 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 5.13 | 80,000 | 410,400 | 1,383,754 | 1.5 M to 1.4 M (-5.47 %) |
May 20 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 3.85 | 10,000 | 38,500 | 1,463,754 | 1.5 M to 1.5 M (-0.68 %) |
May 20 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 3.51 | 20,000 | 70,200 | 1,473,754 | 1.5 M to 1.5 M (-1.34 %) |
Mar 13 2009 | PLX | Protalix BioTherap ... | Shaaltiel Yoseph | Executive VP, R&D | Sell | S | 2.18 | 8,300 | 18,094 | 1,493,754 | 1.5 M to 1.5 M (-0.55 %) |
Page: 1